Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-07-27
2010-02-23
Wang, Shengjun (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S263200
Reexamination Certificate
active
07666891
ABSTRACT:
The present invention relates to a compounds according to formula I, methods for treating diseases mediated by human immunodeficiency virus by administration of a compound according to formula I and pharmaceutical compositions for treating diseases mediated by human immunodeficiency virus containing a compound according to formula I where R1, R2, R3, R4, R5, are as defined herein.
REFERENCES:
patent: 3274185 (1966-09-01), Sigal, Jr. et al.
patent: 3813384 (1974-05-01), Vogelsang et al.
patent: 4826990 (1989-05-01), Musser et al.
patent: 4942236 (1990-07-01), Musser et al.
patent: 5103014 (1992-04-01), Musser et al.
patent: 5331002 (1994-07-01), Miller et al.
patent: 5436252 (1995-07-01), Sorensen et al.
patent: 6248769 (2001-06-01), Cavalla et al.
patent: 7208509 (2007-04-01), Dunn et al.
patent: 0 273 309 (1995-01-01), None
patent: 0 273 310 (1995-06-01), None
patent: WO 97/40017 (1997-10-01), None
patent: WO 98/04135 (1998-02-01), None
patent: WO 00/03998 (2000-01-01), None
patent: WO 02/38553 (2002-05-01), None
patent: WO 02/40021 (2002-05-01), None
patent: WO 02/40021 (2002-05-01), None
patent: WO 2004/085411 (2004-10-01), None
Vipagunta et al. Advanced Drug Delivery Reviews, 2001, vol. 48, pp. 3-26.
West, Solid State Chemistry and its applications, 1988, pp. 358& 365.
Ulrich, Crystallization, Chapter 4, Kirk-othmer Encyclopedia of Chemical Technology, Aug. 2002.
Sension “Initial therapy for Human Immunodeficiency virus:broadening the options,” HIV Clinical Trials, 2004, Vo. 5, No. 2, pp. 99-111.
Buckheit, Jr., Robert W., Non-nucleoside reverse transcriptase inhibitors: perspectives on novel therapeutic compounds and strategies for the treatment of HIV infection,Expert Opinion, Investigative Drugs, Ashley Publications, Ltd., 2001, pp. 1423-1442, vol. 10, No. 8.
Bundgaard, H.,Design of Prodrugs: Bioreversible derivatives for various functional groups and chemical entities in Design of Prodrugs, H. Bundgaard (ed) Elsevier Science Publishers, Amersterdam 1985, pp. 10-27.
De Clercq, Erik, “New Developments in Anti-HIV Chemotherapy,”Current Medicinal Chemistry, 2001, pp. 1543-1572, vol. 8, No. 13, Bentham Science Publishers Ltd.
Del Olmo, Esther, et al., “Anti-Trypanosoma Activity of Some Natural Stilbenoids and Synthetic Related Heterocyclic Compounds”,Bioorganic&Medicinal Chemistry Letters, 2001, pp. 2755-2757, No. 11.
Del Olmo, Esther, et al., “Leishmanicidal Activity of Some Stilbenoids and Related Heterocyclic Compounds,”Bioorganic&Medicinal Chemistry Letters, 2001, pp. 2123-2126, No. 11.
Ettmayer, P., et al., “Lessons Learned from Marketed and Investigational Prodrugs”,J. Med. Chem. 2004 47(10): 2393-2404.
Rosen, Gerald M., et al., “2-Benzyl-1,3,4-oxadiazolin-5-one and Related Compounds,”Notes, Dept. Of Chemistry, Clarkson College of Technology, Potsdam, NY, Aug. 1971, pp. 659-662.
Varia, S. A., “Phenytoin Prodrugs III: Water soluble prodrugs for Oral and/or Parental Use,”J. Pharm. Sci., 1984 73(8):1068-1073.
Dunn James Patrick
Elworthy Todd Richard
Stefanidis Dimitrios
Sweeney Zachary Kevin
Buckwaller Brian L.
Roche Palo Alto LLC
Wang Shengjun
LandOfFree
Heterocyclic antiviral compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic antiviral compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic antiviral compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4219158